Table 2. Clinical characteristics of the patients according to neutrophil-to-lymphocyte ratio.
| NLR < 3 (n=118) | NLR ≥ 3 (n= 60) | p-value | ||
|---|---|---|---|---|
| Age, year, median (IQR) | 67.94 (63.33-76.97) | 74.45 (44.75-80.41) | 0.02 | |
| Gender, no. (%) | ||||
| Female | 20 (16.9) | 10 (16.7) | ||
| Male | 98 (83.1) | 50 (83.3) | ||
| BMI, median (IQR) | 27.29 (24.22-32.44) | 27.15 (24.20-28.39) | 0.44 | |
| Hypertension, no. (%) | 70 (59.3) | 38 (63.3) | 0.60 | |
| Diabetes, no. (%) | 32 (27.1) | 22 (36.7) | 0.19 | |
| Dyslipidemia, no. (%) | 22 (18.6) | 14 (23.3) | 0.46 | |
| NLR, median (IQR) | 1.94 (1.57-2.41) | 4.02 (3.55-4.82) | <0.01 | |
| Pathologic stage, no. (%) | 0.03 | |||
| pTa | 103 (87.28) | 44 (73.3) | ||
| pT1 | 15 (12.72) | 16 (26.6) | ||
| Pathologic grade, no. (%) | 0.22 | |||
| Low grade | 90 (76.27) | 36 (60.0) | ||
| High grade | 28 (23.73) | 24 (40.0) | ||
| Concomitant CIS, no. (%) | 0.01 | |||
| No | 98 (83.05) | 24 (40.0) | ||
| Yes | 20 (16.94) | 36 (60.0) | ||
| No. of tumours (%) | 0.04 | |||
| 1 | 90 (76.28) | 28 (46.6) | ||
| 2-7 | 28 (23.72) | 26 (43.4) | ||
| ≥ 8 | 0 (0) | 6 (10.0) | ||
| Tumour size, cm, no. (%) | 0.60 | |||
| < 3 cm | 67 (56.78) | 29 (48.33) | ||
| ≥ 3 cm | 51 (43.22) | 31 (51.66) | ||
| Smoking status | 0.06 | |||
| Never | 12 (10.2) | 6 (10.0) | ||
| Former | 63 (53.4) | 11 (18.3) | ||
| Current | 43 (36.4) | 43 (71.7) | ||
| EORTC Recurrence | 0.34 | |||
| Low | 32 (27.1) | 16 (26.7) | ||
| Intermediate | 86 (72.9) | 40 (66.6) | ||
| High | 0 (0.0) | 4 (6.7) | ||
| EORTC Progression | 0.15 | |||
| Low | 39 (33.0) | 19 (31.7) | ||
| Intermediate | 62 (52.5) | 20 (33.3) | ||
| High | 17 (14.5) | 21 (35.0) | ||
| Chemotherapy instillation | 90 (76.27) | 40 (66.6) | 0.17 | |
| Immunotherapy instillation | 10 (8.5) | 9 (15.0) | 0.18 | |
IQR = interquartile range; BMI = body mass index; NLR = neutrofil-to-lymphocyte ratio; CIS = carcinoma in situ